NCT01784861View on ClinicalTrials.gov

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 3, 2013

Primary Completion Date

August 19, 2020

Study Completion Date

August 19, 2020

Conditions
AdenocarcinomaPancreatic Neoplasms
Interventions
DRUG

X-82

DRUG

Everolimus

Trial Locations (2)

37232

Vanderbilt University, Nashville

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Tyrogenex
All Listed Sponsors
collaborator

Tyrogenex

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01784861 - VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter